Anti-infective and oncology pharmaceutical company, Venus Remedies Limited, announced Monday it received a product patent grant for its unique research product, Vancoplus from the Indian Patent Office. It is valid till 2025.
“It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product. It is one the best and safest option to address MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens”, according to Dr. Manu Chaudhary, Joint Managing Director, Venus Remedies Limited.
Vancoplus is a novel antibiotic adjuvant entity highly effective against notorious (MRSA) strain and multi-drug resistant microbes primarily responsible for causing infections such as Meningitis, Pneumonia, Typhoid, Septicemia, Urinary Tract Infection, Skin infections and Staphylococcal Endocarditis.
It is also active against different mechanisms of resistance such as cell membrane impermeability, efflux pumps, biofilms, which no other existing therapeutic options available in the market are able to address.
Vancoplus has already been launched in the Indian market and to date approximately 80,000 patients have been cured with it. It has received an overwhelming response from the medical fraternity in India.
Venus has already received patent grant for Vancoplus from more than 18 countries including USA, Japan, South Africa, New Zealand , Ukraine, Australia and South Africa.
